Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...
WebMD11h
New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...
Strong Wegovy revenue growth for Novo Nordisk but shares dip
Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...
Wegovy sales are slaying for Novo Nordisk right now
Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk, which are designed to treat type 2 ...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Novo beats Eli Lilly in Q3 sales for obesity drug
Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.